OneAscent Financial Services LLC cut its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 33.9% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,824 shares of the company’s stock after selling 4,528 shares during the quarter. OneAscent Financial Services LLC’s holdings in Johnson & Johnson were worth $2,336,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently made changes to their positions in JNJ. National Pension Service increased its stake in shares of Johnson & Johnson by 1.3% in the 2nd quarter. National Pension Service now owns 5,226,968 shares of the company’s stock valued at $1,327,493,000 after buying an additional 67,484 shares during the period. IFP Advisors Inc increased its stake in Johnson & Johnson by 8.8% in the second quarter. IFP Advisors Inc now owns 38,760 shares of the company’s stock valued at $9,844,000 after purchasing an additional 3,133 shares in the last quarter. Elefante Mark B increased its holdings in shares of Johnson & Johnson by 9.8% in the second quarter. Elefante Mark B now owns 28,686 shares of the company’s stock worth $7,285,000 after acquiring an additional 2,563 shares in the last quarter. AMG Asset Management Group Inc. raised its holdings in shares of Johnson & Johnson by 172.0% during the third quarter. AMG Asset Management Group Inc. now owns 3,852 shares of the company’s stock worth $1,020,000 after acquiring an additional 2,436 shares during the period. Finally, Gradient Investments LLC raised its position in Johnson & Johnson by 9.9% in the 2nd quarter. Gradient Investments LLC now owns 152,831 shares of the company’s stock valued at $38,815,000 after buying an additional 13,737 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently issued reports on the company. Guggenheim reiterated a “buy” rating and set a $287.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 7th. TD Cowen reissued a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 20th. Evercore set a $300.00 price target on Johnson & Johnson in a research report on Tuesday, October 20th. Raymond James Financial set a $280.00 price objective on Johnson & Johnson in a research report on Monday, August 3rd. Finally, Wells Fargo & Company lifted their target price on Johnson & Johnson from $275.00 to $287.00 and gave the stock an “overweight” rating in a research note on Friday, October 16th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $275.92.
View Our Latest Stock Report on JNJ
Johnson & Johnson Trading Down 2.1%
JNJ stock opened at $272.75 on Thursday. The company’s 50-day simple moving average is $267.42 and its 200 day simple moving average is $250.61. Johnson & Johnson has a 52 week low of $199.38 and a 52 week high of $290.25. The company has a market capitalization of $656.58 billion, a PE ratio of 41.33, a price-to-earnings-growth ratio of 2.75 and a beta of 0.22. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The company had revenue of $25.40 billion for the quarter, compared to analysts’ expectations of $25.38 billion. During the same period last year, the firm earned $2.80 earnings per share. The business’s revenue for the quarter was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, sell-side analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current year.
Johnson & Johnson Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be paid a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio (DPR) is 81.21%.
Insiders Place Their Bets
In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the transaction, the executive vice president directly owned 25,447 shares of the company’s stock, valued at $6,991,308.78. The trade was a 56.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Elizabeth Forminard sold 13,072 shares of the company’s stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $284.39, for a total value of $3,717,546.08. Following the sale, the executive vice president owned 16,994 shares of the company’s stock, valued at approximately $4,832,923.66. The trade was a 43.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.16% of the stock is owned by company insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.
See Also
- Five stocks we like better than Johnson & Johnson
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
